Bli medlem
Bli medlem

Du är här

2016-11-17

PCI Biotech Holding: KEY INFORMATION RELATING TO THE PROPOSED UNDERWRITTEN RIGHTS ISSUE IN PCI BIOTECH HOLDING ASA

Reference is made to the Company's announcement on 17 November 2016 regarding
a underwritten rights issue proposed resolved at an extraordinary general
meeting on 8 December 2016. The rights issue is subject to shareholder
approval and a prospectus approved by the Norwegian Financial Supervisory
Authority and published by the Company.

Key information in relation to the proposed rights issue:
Date on which the proposed terms and conditions of the rights issue were
announced: 17 November 2016
Last day including right: 8 December 2016
Ex-date: 9 December 2016
Record date: 12 December 2016
Date of approval: Not yet approved. Proposed that the extraordinary general
meeting to be held at 8 December 2016 approves the rights issue
Maximum number of new shares: 10,000,000 new shares
Subscription price per share: NOK 7

This information is published in accordance with the requirements of
Continuing Obligations of stock exchange listed companies.

For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo

Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.